Globus Medical (GMED) Receives Daily Media Sentiment Rating of 0.28

News stories about Globus Medical (NYSE:GMED) have been trending positive recently, AlphaOne Sentiment Analysis reports. The research firm, a subsidiary of Accern, scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Globus Medical earned a coverage optimism score of 0.28 on AlphaOne’s scale. AlphaOne also assigned press coverage about the medical device company an impact score of 86 out of 100, indicating that recent press coverage is very likely to have an effect on the company’s share price in the next several days.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Shares of Globus Medical (NYSE GMED) traded up 0.73% on Friday, hitting $32.95. 691,462 shares of the stock traded hands. Globus Medical has a one year low of $19.25 and a one year high of $33.11. The stock has a 50 day moving average of $31.39 and a 200 day moving average of $28.05. The company has a market cap of $3.17 billion, a PE ratio of 30.23 and a beta of 0.63.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Wednesday, May 3rd. The medical device company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.02. The company had revenue of $155.81 million for the quarter. Globus Medical had a net margin of 18.09% and a return on equity of 14.15%. Equities analysts anticipate that Globus Medical will post $1.27 earnings per share for the current year.

Several equities research analysts recently weighed in on GMED shares. Aegis reissued a “buy” rating and set a $31.00 price target on shares of Globus Medical in a research report on Tuesday, February 28th. Oppenheimer Holdings, Inc. set a $29.00 price target on shares of Globus Medical and gave the company a “hold” rating in a research report on Tuesday, February 28th. Leerink Swann raised shares of Globus Medical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 12th. Barclays PLC downgraded shares of Globus Medical from an “equal weight” rating to an “underweight” rating and raised their price target for the company from $24.00 to $28.00 in a research report on Monday, April 24th. Finally, Canaccord Genuity raised shares of Globus Medical from a “hold” rating to a “buy” rating and raised their price target for the company from $30.00 to $37.00 in a research report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $28.90.

WARNING: This story was published by Mideast Time and is owned by of Mideast Time. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.mideasttime.com/globus-medical-gmed-receives-daily-media-sentiment-rating-of-0-28/1787049.html.

In other Globus Medical news, President Anthony L. Williams sold 16,153 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $31.94, for a total transaction of $515,926.82. Following the transaction, the president now directly owns 16,153 shares of the company’s stock, valued at $515,926.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 28.21% of the company’s stock.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “GMED”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.